Results 61 to 70 of about 4,576,202 (266)

Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma

Zhongliu Fangzhi Yanjiu, 2018
Objective To analyze clinical features of lymphoblastic lymphoma(LBL), compare clinical and prognostic characteristics of B lymphoblasts lymphoma (B-LBL) and T lymphoblasts lymphoma (T-LBL), and the prognosis of various chemotherapy regimens on LBL ...
YUAN Ying, ZANG Li, YUE Zhijie, ZHANG Yizhuo, WANG Xiaofang   +4 more
doaj   +1 more source

Ironic Medications: A Narrative‐Based Psycho‐Educational Intervention to Explore Patient–Provider Communication in Adolescents With Haematological Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adolescents with haematological malignancies face significant emotional and relational challenges, often accompanied by difficulties in communicating their needs within the healthcare context. To address these issues, a narrative‐based psycho‐educational intervention based on the creation and prescription of Ironic Medications was ...
Marta Stoppa, Elena Pagani Bagliacca, Selena Russo, Giulia Rampoldi, Maria Grazia Strepparava, Adriana Cristina Balduzzi, Andrea Biondi, Marco Spinelli   +7 more
wiley   +1 more source

Atypical Mitochondrial Phenotype of Colonic CD4+ and CD8+ T Cells During Experimental Chronic Colitis

Biomedicines
Background: Patients with ulcerative colitis (UC) suffer from a chronic relapsing-remitting inflammatory bowel disease and show heterogeneous disease severity and therapy response.
Jonas Negele, Tobias Franz, Anna Krone, Marc Roder, Elif Gelmez, Nouria Jantz-Naeem, Olivia Kershaw, Verena Keitel-Anselmino, Andreas Jeron, Dunja Bruder, Sascha Kahlfuß   +10 more
doaj   +1 more source

B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment

OncoImmunology, 2017
Evidence of tumor-resident mature B cell and antibody compartments and reports of associations with favorable prognosis in malignant melanoma suggest that humoral immunity could participate in antitumor defense.
Giulia Chiaruttini, Silvia Mele, James Opzoomer, Silvia Crescioli, Kristina M. Ilieva, Katie E. Lacy, Sophia N. Karagiannis   +6 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

OncoImmunology, 2017
Chronic lymphocytic leukemia (CLL) is associated with a profound dysregulation of the immune system. Loss of T cell function is frequently caused in cancer by sustained signaling of inhibitory receptors. Here, we analyzed the role of the novel inhibitory
Mónica Villa-Álvarez, Seila Lorenzo-Herrero, Ana P. Gonzalez-Rodriguez, Alejandro López-Soto, Angel R. Payer, Esther Gonzalez-Garcia, Leticia Huergo-Zapico, Segundo Gonzalez   +7 more
doaj   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source

The regulatory capacity of B cells directs the aggressiveness of CLL

OncoImmunology, 2019
Chronic lymphocytic leukemia (CLL) is associated with abnormal T-cell responses responsible for defective anti-tumor activities. Intriguingly, CLL B cells share phenotypical characteristics with regulatory B (Breg) cells suggesting that they might ...
Audrey Mohr, Marie Cumin, Cristina Bagacean, Pierre Pochard, Christelle Le Dantec, Sophie Hillion, Yves Renaudineau, Christian Berthou, Adrian Tempescul, Hussam Saad, Jacques-Olivier Pers, Anne Bordron, Christophe Jamin   +12 more
doaj   +1 more source

Antigen specific B cells in myasthenia gravis patients

Immunological Medicine, 2020
Myasthenia gravis (MG) is a disease caused by pathogenic autoantibodies against the neuromuscular junction and is characterized by muscle weakness. Most MG patients produce antibodies against the acetylcholine receptor (AChR), but a subset of patients ...
Kazushiro Takata, Makoto Kinoshita, Hideki Mochizuki, Tatsusada Okuno   +3 more
doaj   +1 more source

BMT4me En Español: Multisite Feasibility and Usability Testing of a Spanish‐Language mHealth Adherence Support App for Spanish‐Speaking Caregivers of Children After Hematopoietic Stem Cell Transplantation and Cancer Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Medication nonadherence during the first 100 days after pediatric hematopoietic stem cell transplantation (HSCT) and during oncology treatment increases risk for complications. BMT4me is a caregiver‐facing mobile health (mHealth) application providing medication reminders, symptom tracking, and note‐taking features to support ...
Micah A. Skeens, Madeline R. Peek, Bianca Franklin, Emre Sezgin, Melissa Beauchemin   +4 more
wiley   +1 more source